Comparison of Two Assays to Determine Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis in relation to Other Chronic Inflammatory Rheumatic Diseases: Assaying Anti-Modified Citrullinated Vimentin Antibodies Adds Value to Second-Generation Anti-Citrullinated Cyclic Peptides Testing

Table 2

Concordance between the results of assays for anti-CCP2 and anti-MCV in rheumatoid arthritis.

		Anti-CCP2
		Positive; 𝑛=94 (66.2%)	Negative; 𝑛=48 (33.8%)
Anti-MCV	Positive
	𝑛=115 (81.0%)	88 (61.97%)	27 (19.01%)
	Negative
	𝑛=27 (19.0%)	6 (4.22%)	21 (14.78%)

Total patients with RA assessed = 142, and values in parenthesis represent the percentage of the total 142 patients.
Kappa = 0.42.